You are here

Article Text

Article menu
Download PDFPDF
Matters arising
Probable adverse effects of long term use of somatostatin analogues in patients with RA
  1. S Marcora1,
  2. A Lemmey1,
  3. P Maddison2
  1. 1School of Sport, Health and Exercise Sciences, University of Wales, Bangor, UK
  2. 2Rheumatology Department, Gwynedd Hospital, UK
  1. Correspondence to:
    Mr S Marcora, School of Sport, Health and Exercise Sciences, University of Wales, Bangor, George Building, Holyhead Road, Bangor, Gwynedd LL57 2PX, UK;
    s.m.marcora{at}bangor.ac.uk

https://doi.org/10.1136/ard.61.12.1117

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We would like to comment on two pilot studies recently published in the Annals of the Rheumatic Diseases by Paran et al and Koseoglu and Koseoglu about the effects of otcreotide, a somatostatin (SOM) analogue, in patients with refractory rheumatoid arthritis (RA).1,2 Both groups reported minor adverse effects as shown by routine clinical and laboratory assessment. However, because these SOM analogues had some positive effects on disease activity in these difficult patients, they concluded that they might be used as disease modifying antirheumatic drugs (DMARDs) and that larger randomised controlled clinical trials were warranted.

    Although we welcome research on new DMARDs, in this instance we feel obliged to point out some probable adverse effects of the long term use of SOM analogues in …

    View Full Text